Evidence map›Paper›PMID 39245714›Full record

ArticleTrials2024

Effectiveness of structured, multidisciplinary long-term care for pediatric cancer survivors: protocol of the multicenter, randomized-controlled AELKI study.

Hannah Schmidt, Katja Baust, Gabriele Calaminus, Lisa Hohls, Katharina Tetzner, Nicole Griech, Henrike Haugke, Hannah Baltus, Susanne Elsner, Alexander Katalinic and 17 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Hannah Schmidt *Clinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. hannah.schmidt@uksh.de.ORCID http://orcid.org/0000-0002-9393-5862
Katja Baust *Center for Pediatrics, Bonn University Hospital, Bonn, Germany.
Gabriele CalaminusCenter for Pediatrics, Bonn University Hospital, Bonn, Germany.
Lisa HohlsClinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Katharina TetznerCenter for Pediatrics, Bonn University Hospital, Bonn, Germany.
Nicole GriechCenter for Pediatrics, Bonn University Hospital, Bonn, Germany.
Henrike HaugkeCenter for Pediatrics, Bonn University Hospital, Bonn, Germany.
Hannah BaltusInstitute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
Susanne ElsnerInstitute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
Alexander KatalinicInstitute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
Hera BeckerClinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Chirine CyteraClinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Judith GebauerDepartment of Internal Medicine 1, University Hospital Schleswig-Holstein, Lübeck, Germany.
Ann-Kristin Kock-SchoppenhauerIT Center for Clinical Research, University of Lübeck, Lübeck, Germany.
Anke NeumannIT Center for Clinical Research, University of Lübeck, Lübeck, Germany.
Christian DenzerDepartment of Pediatrics and Adolescent Medicine, Section of Pediatric Endocrinology and Diabetology Hormone Center for Children and Adolescents, Ulm University Hospital, Ulm, Germany.
Michael M SchündelnDivision of Pediatric Hematology and Oncology, Department of Pediatrics III, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
Jörg FaberCenter for Pediatric and Adolescent Medicine, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany.
Conny SattlerClinic for Pediatric and Adolescent Medicine, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Michael C FrühwaldPediatrics and Adolescent Medicine, University Medical Center Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.
Anja Borgmann-StaudtDepartment of Pediatrics With Focus On Oncology/Hematology, Charité Medical Center Berlin, Berlin, Germany.
Anke BarnbrockDepartment of Pediatrics, Division of Hematology, Oncology and Hemostaseology, Goethe University, Frankfurt, Frankfurt/Main, Germany.
Markus MetzlerClinic for Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Gabriele EscherichDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Inke R KönigInstitute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.
Ingo Menrath *Clinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Thorsten Langer *Clinic for Pediatric and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Germany, around 2.250 children and adolescents are diagnosed with cancer each year. Despite generally positive long-term survival rates, many patients must cope with late effects of the disease and its treatment. This highlights the need for a well-structured, long-term approach addressing both physical and mental health issues. Currently, the German healthcare system lacks such comprehensive structures. Our study aims to evaluate the effectiveness of a structured, multidisciplinary long-term approach compared to conventional "treatment as usual" (TAU).

methodsA prospective, multicenter study with ten pediatric university clinics in Germany will be conducted. The cluster-randomization takes place at the clinic level. Children and adolescents who completed their cancer treatment at least five years ago and their parents will be eligible to participate. While the control group (CG) receives TAU, the intervention group (IG) participates in a structured program. This program includes risk-based medical treatment and psychosocial interventions tailored to each patient's individual needs within a two-month timeframe. The primary outcome is the improvement of self-efficacy. Secondary outcomes are satisfaction with health care, improvement of health-related quality of life (HRQoL), reduction of mental health problems, and improvement of transition readiness. DISCUSSION: This approach has the potential to optimize the health care for individuals who survived cancer during childhood or adolescence. It addresses the challenges of overuse, underuse, and misuse of health care resources. By considering both medical and psychosocial factors and promoting increased self-efficacy, independent from parental involvement, it may facilitate a smoother transition to adult medicine and enhance adherence to lifelong aftercare. If proven successful, this approach will contribute to the integration of multidisciplinary strategies into standard healthcare practice.

trial registrationGerman Clinical Trials Register DRKS00029269. Registered on December 23, 2022.

Indexed as

Cancer SurvivorsMulticenter Studies as TopicNeoplasmsQuality of LifeRandomized Controlled Trials as TopicAdaptation, PsychologicalAdolescentChildFemaleGermanyHumansLong-Term CareMaleMental HealthPatient Care TeamPatient SatisfactionCancerChildren and adolescentLong-term careMultidisciplinaryPsychosocial

Identifiers

PMID39245714
PMCPMC11382442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.